Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Shares of Axsome Therapeutics AXSM jumped 20.2% on Monday after the company announced that it has entered into a settlement ...

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

TD Cowen adjusted its outlook on Axsome Therapeutics (NASDAQ:AXSM), a $6.16 billion market cap company, by increasing the price target to $190 from the previous $155, while maintaining a Buy rating on ...

Teva has not raised capital since it acquired Actavis from Allergan in 2016 - a deal worth nearly $40 billion and for which ...

Shares of Axsome Therapeutics ( AXSM -0.49%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...

EST Teva (TEVA) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' ...

What do the analysts say? Following the release of the quarterly report, Bank of America cut its price target for Teva from $26 to $23, a price that represents a 29.7% premium on the price in New York ...

Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...